-
The Malaysian Journal of Pathology Apr 2022The ameloblastoma is the most challenging odontogenic neoplasm to treat because of its locallyinvasive behaviour, severe clinical implication, risk of malignant...
The ameloblastoma is the most challenging odontogenic neoplasm to treat because of its locallyinvasive behaviour, severe clinical implication, risk of malignant transformation and high recurrence rate. Recent evidence suggests that BRAF, EGFR and CD10 have a role in the local invasiveness of ameloblastoma. However, the spatial distribution characteristics of these pro-invasive factors and their association with clinical parameters in this neoplasm are largely unexplored. We sought to address these issues in ameloblastoma subtypes and to determine their biological relevance. Nineteen unicystic (UA) and 20 conventional ameloblastoma (SMA) were subjected to immunohistochemical staining for BRAF, EGFR and CD10, and semiquantitative analysis was performed. All ameloblastoma cases (n=39/39; 100%) exhibited a BRAF+/EGFR+/CD10+immunoprofile. Their expression rates were significantly higher in SMA than UA (P<0.05). BRAF, essential for the progression and proliferation of ameloblastoma, was detected mainly in the cytoplasm of stellate reticulum-like>stromal>preameloblast- like cells (P<0.05). EGFR, a potent oncogenic protein, showed predominantly nuclear localisation. CD10, an apoptosis-inhibitory factor, was strongly expressed in the membrane of stellate reticulum-like cells. Taken together, present results suggest that the spatial distribution patterns of BRAF, EGFR and CD10 parallel the specific behaviours of SMA and UA. Their cellular and intracellular protein localisations have important targeted therapy implications.
Topics: Ameloblastoma; ErbB Receptors; Humans; Neprilysin; Odontogenic Tumors; Proto-Oncogene Proteins B-raf
PubMed: 35484883
DOI: No ID Found -
Journal of Istanbul University Faculty... 2017Odontogenic tumors are a heterogeneous group of lesions of diverse clinical behavior and histopathologic types, ranging from hamartomatous lesions to malignancy. Because... (Review)
Review
Odontogenic tumors are a heterogeneous group of lesions of diverse clinical behavior and histopathologic types, ranging from hamartomatous lesions to malignancy. Because odontogenic tumors arise from the tissues which make our teeth, they are unique to the jaws, and by extension almost unique to dentistry. Odontogenic tumors, as in normal odontogenesis, are capable of inductive interactions between odontogenic ectomesenchyme and epithelium, and the classification of odontogenic tumors is essentially based on this interaction. The last update of these tumors was published in early 2017. According to this classification, benign odontogenic tumors are classified as follows: Epithelial, mesenchymal (ectomesenchymal), or mixed depending on which component of the tooth germ gives rise to the neoplasm. Malignant odontogenic tumors are quite rare and named similarly according to whether the epithelial or mesenchymal or both components is malignant. The goal of this review is to discuss the updated changes to odontogenic tumors and to review the more common types with clinical and radiological illustrations.
PubMed: 29354306
DOI: 10.17096/jiufd.52886 -
Cell Proliferation Jul 2021The treatment of ameloblastoma, an odontogenic epithelial tumour destroying jawbone, mainly depends on radical destructive resections. Other therapeutic options are...
OBJECTIVES
The treatment of ameloblastoma, an odontogenic epithelial tumour destroying jawbone, mainly depends on radical destructive resections. Other therapeutic options are limited by the characteristics of ameloblastoma, such as high recurrence rates and resistance to radiation and chemotherapy, which implies possible existence of cancer stem cells (CSCs) in ameloblastoma. Here, we identified a putative CSC population in immortalized and primary human ameloblastoma cells and examined possible therapeutic reagents to reduce the CSC population.
METHODS
We investigated subpopulations of AM-1 cell line and human ameloblastoma cells using immunocytochemistry and flow cytometry and the effects of Wnt signalling activators on the 2- and 3-dimensional cultured ameloblastoma cells using molecular biological analyses.
RESULT
Among heterogenous ameloblastoma cells, small-sized and round-shaped cells were found to be proliferative and expressed a marker of dental epithelial stem cells, SRY-box 2 (Sox2). Exogenous activation of Wnt signalling using glycogen synthase kinase 3β inhibitors, lithium chloride (LiCl) and valproic acid (VPA), increased the cell size and decreased proliferation of cells and expression of Sox2 in 2 dimensionally cultured AM-1 and human primary ameloblastoma cells. Furthermore, the growth of 3 dimensionally cultured AM-1 cells as suspended or embedded in gel was suppressed by treatment with Wnt signalling activators, VPA and CHIR99021, or antibodies to sclerostin, an antagonist of Wnt signalling.
CONCLUSION
We suggest that Wnt signalling activators are potential drug candidates to suppress CSCs in ameloblastoma.
Topics: Ameloblastoma; Animals; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cell Size; Down-Regulation; Humans; Lithium Chloride; Mice; Mice, Nude; Neoplastic Stem Cells; SOXB1 Transcription Factors; Valproic Acid; Wnt Signaling Pathway; beta Catenin
PubMed: 34096124
DOI: 10.1111/cpr.13073 -
Asian Pacific Journal of Cancer... Nov 2022Ameloblastoma is regarded as the second most prevalent odontogenic tumor in the light of its prevalence, clinical characteristics, greater incidence of tumor recurrence,... (Meta-Analysis)
Meta-Analysis
INTRODUCTION
Ameloblastoma is regarded as the second most prevalent odontogenic tumor in the light of its prevalence, clinical characteristics, greater incidence of tumor recurrence, and therapeutic challenges. The aim of this systematic review was to establish the prevalence of ameloblastoma in the Indian subcontinent and to establish a national epidemiologic profile for these lesions.
MATERIAL AND METHODS
A systematic review was undertaken based on the PRISMA guidelines in search of epidemiologic studies concerning odontogenic tumors and ameloblastoma that are listed by PubMed, EBSCO, and Google Scholar embracing the period from January 2010 to December 2021, to evaluate the prevalence rate in India. A total of 277 publications were retrieved, of which 27 articles were selected, based on the World Health Organization classification of odontogenic tumors.
RESULTS
The affected individuals were on average in the third decade of life, with a higher male predominance. The majority of the tumors were multilocular radiolucencies in the posterior mandible, with follicular and plexiform histopathological features. The most common type of malignant lesion is ameloblastic carcinoma. Over 60% of follicular ameloblastoma recurred more frequently than the other types of ameloblastoma.The random effect model shows overall point estimate of 4.83 with 95% confidence interval (4.44 -5.26).
CONCLUSION
The systematic study indicates a slight male predisposition to ameloblastoma, with a peak incidence in the third decade of life and the mandible as the preferred anatomical site. The solid/multicystic ameloblastoma is the most prevalent histopathologic pattern. More epidemiological research on the prevalence rate of ameloblastoma is required, particularly in India, in an effort to accurately determine the national epidemiological profile of ameloblastoma.
Topics: Male; Humans; Female; Ameloblastoma; Prevalence; India; Odontogenic Tumors; Genotype
PubMed: 36444570
DOI: 10.31557/APJCP.2022.23.11.3601 -
Journal of Molecular Medicine (Berlin,... Apr 2015Rare conditions are sometimes ignored in biomedical research because of difficulties in obtaining specimens and limited interest from fund raisers. However, the study of... (Review)
Review
Rare conditions are sometimes ignored in biomedical research because of difficulties in obtaining specimens and limited interest from fund raisers. However, the study of rare diseases such as unusual cancers has again and again led to breakthroughs in our understanding of more common diseases. It is therefore unsurprising that with the development and accessibility of next-generation sequencing, much has been learnt from studying cancers that are rare and in particular those with uniform biological and clinical behavior. Herein, we describe how shotgun sequencing of cancers such as granulosa cell tumor, endometrial stromal sarcoma, epithelioid hemangioendothelioma, ameloblastoma, small-cell carcinoma of the ovary, clear-cell carcinoma of the ovary, nonepithelial ovarian tumors, chondroblastoma, and giant cell tumor of the bone has led to rapidly translatable discoveries in diagnostics and tumor taxonomies, as well as providing insights into cancer biology.
Topics: Animals; Genomics; High-Throughput Nucleotide Sequencing; Humans; Mutation; Neoplasms
PubMed: 25676695
DOI: 10.1007/s00109-015-1260-8 -
Nigerian Journal of Clinical Practice Oct 2022Ameloblastoma is a benign epithelial odontogenic tumor with a tendency for recurrence. Some recurrent tumors could behave unpredictably with atypical microscopic changes.
CONTEXT
Ameloblastoma is a benign epithelial odontogenic tumor with a tendency for recurrence. Some recurrent tumors could behave unpredictably with atypical microscopic changes.
AIM
To study the clinicopathologic features and diagnoses of recurrent tumors of ameloblastoma.
SETTINGS AND DESIGN
This is a 5-year (2012-2017) retrospective study of 17 consecutive patients with recurrent tumors of ameloblastoma in a Teaching Hospital in Enugu.
METHODS AND MATERIAL
The relevant clinicopathologic information, histology slides, and blocks were retrieved and reviewed. Descriptive analysis was used to determine the frequency, tables for categorical variables, and a Chi-square test was used to determine the statistical significance.
RESULT
Recurrent tumors constituted 33.3% (17/51) of all confirmed diagnoses of ameloblastoma. The histopathologic diagnosis of the recurrent tumors includes conventional ameloblastoma 58.8% (10/17), unicystic ameloblastoma 5.9% (1/17), and ameloblastic carcinoma 35.3% (6/17). There was bilateral mandibular involvement in 60.0%, pain 58.8%, ulceration 29.4%, and matted lymph nodes 5.9%. Tumors with positive fluid aspirates 82.4% (14/17) yielded dark-brown fluids in 90.0% (9/10) of recurrent ameloblastomas and in 66.7% (2/3) of ameloblastic carcinomas.
CONCLUSION
There was a high recurrence rate of recurrent tumors of ameloblastoma demonstrated in the present study, with a malignant presentation in some cases.
Topics: Humans; Ameloblastoma; Retrospective Studies; Nigeria; Odontogenic Tumors; Hospitals, Teaching
PubMed: 36308255
DOI: 10.4103/njcp.njcp_82_22 -
Journal of Cancer Research and... 2019Metastasizing ameloblastoma (MA) is a very rare odontogenic tumor with 2% of incidence rate. It exhibits benign histopathological features and malignant intrinsic... (Review)
Review
Metastasizing ameloblastoma (MA) is a very rare odontogenic tumor with 2% of incidence rate. It exhibits benign histopathological features and malignant intrinsic quality in the form of metastasis which makes it a little more than a pathological curiosity. Various molecular aspects related with malignant behavior have been discussed. Because of this, it provides a diagnostic challenge for clinicians and surgeons. It is an elusive lesion which should be more researched and studied so that definitive diagnostic features can be put forward. The objective of this paper is to review the molecular aspect involved in the pathogenesis of MA which will aid in differentiating non-MA from MA and thus helping in providing proper treatment at an early stage.
Topics: Ameloblastoma; Biomarkers, Tumor; Disease Management; Disease Susceptibility; Epithelial-Mesenchymal Transition; Humans; Neoplasm Metastasis; Neoplasm Staging; Tumor Microenvironment
PubMed: 31169204
DOI: 10.4103/jcrt.JCRT_268_17 -
Nigerian Journal of Clinical Practice Sep 2022Ameloblastoma is a benign epithelial odontogenic tumor with a tendency for recurrence. The recurrent tumors behave unpredictably with atypical microscopic changes and...
BACKGROUND
Ameloblastoma is a benign epithelial odontogenic tumor with a tendency for recurrence. The recurrent tumors behave unpredictably with atypical microscopic changes and likelihood of malignant transformation.
AIMS
To study the clinicopathologic features and diagnostic outcome of recurrent tumors of ameloblastoma in Enugu. This is a six-year (2012-2017) retrospective study of 17 consecutive patients with recurrent tumors of ameloblastoma in a Teaching Hospital in Nigeria.
MATERIALS AND METHODS
The relevant clinicopathologic information, histology slides, and blocks were retrieved and reviewed. Descriptive analysis was used to determine the frequency, tables for categorical variables, and a Chi-square test was used to determine the statistical significance.
RESULT
Recurrent tumors constituted 33.3% (17/51) of all confirmed diagnoses of ameloblastoma. The diagnostic outcome of the recurrent tumors was conventional ameloblastoma 58.8% (10), unicystic ameloblastoma 5.9% (1), and ameloblastic carcinoma 35.3% (6). There was bilateral mandibular extension in 60.0% (9), pain 58.8% (10), ulceration 29.4% (5), and matted lymph nodes 5.9% (1). Tumors with positive fluid aspirates 82.4% (14) yielded dark-brown fluids in 90.0% (9) of recurrent ameloblastomas and in 66.7% (2) of ameloblastic carcinomas. Atypical peripheral hyperplasia, nuclear hyperchromatism, and increased vascularization were commonly observed in benign recurrences. The frequency of recurrence is significantly associated with the biological behavior of ameloblastoma P = 0.03.
CONCLUSION
Recurrent tumors of ameloblastoma presented atypical features and malignant transformation.
Topics: Ameloblastoma; Humans; Nigeria; Odontogenic Tumors; Retrospective Studies
PubMed: 36149215
DOI: 10.4103/njcp.njcp_82_22 -
PloS One 2015Malignant ameloblastoma, comprising metastasizing ameloblastoma and ameloblastic carcinoma, represents 1.6-2.2% of all odontogenic tumors. Due to its rare nature,...
BACKGROUND
Malignant ameloblastoma, comprising metastasizing ameloblastoma and ameloblastic carcinoma, represents 1.6-2.2% of all odontogenic tumors. Due to its rare nature, malignant ameloblastoma has only been reported in the literature in small case series or case reports. Using the Surveillance, Epidemiology and End-Results (SEER) database, we have performed a population-based study to determine the incidence rate and the absolute survival of malignant ameloblastoma.
METHOD
Using the International Classification of Diseases for Oncology (ICD-O) codes 9310/3 and 9270/3, data from the SEER database were used to calculate the incidence rate and absolute survival rate of population with malignant ameloblastoma.
RESULTS
The overall incidence rate of malignant ameloblastoma was 1.79 per 10 million person/year. The incidence rate was higher in males than females and also higher in black versus white population. The median overall survival was 17.6 years from the time of diagnosis and increasing age was associated with a statistically significant poorer survival.
CONCLUSIONS
To our best knowledge, we report the largest population-based series of malignant ameloblastoma. The incidence rate was 1.79 per 10 million person/year and the overall survival was 17.6 years.
Topics: Adolescent; Adult; Ameloblastoma; Child; Child, Preschool; Cohort Studies; Databases, Factual; Epidemiological Monitoring; Female; Humans; Incidence; Infant; Infant, Newborn; Jaw Neoplasms; Male; Middle Aged; Survival Rate; Young Adult
PubMed: 25692490
DOI: 10.1371/journal.pone.0117789 -
Medicina Oral, Patologia Oral Y Cirugia... Nov 2023Odontogenic tumours are infrequent lesions. Studies on the frequency of odontogenic tumours from Latin America are scarce. This work aimed to determine the relative... (Review)
Review
BACKGROUND
Odontogenic tumours are infrequent lesions. Studies on the frequency of odontogenic tumours from Latin America are scarce. This work aimed to determine the relative frequency of odontogenic tumours in a Chilean population using the 2022 World Health Organization classification.
MATERIAL AND METHODS
This is a case series retrospective study. We reviewed 35,530 samples from 1975 to 2022 from the Oral Pathology Referral Institute and the Pathological Anatomy Service, Faculty of Dentistry, University of Chile. We utilized the 2022 World Health Organization classification for histological typification.
RESULTS
According to 2022 World Health Organization classification, 544 odontogenic tumours were confirmed. The most frequent odontogenic tumours were: odontoma (n=241; 44.3%), ameloblastoma (n=109; 20.0%) and cemento-ossifying fibroma (n=71; 13.1%). Benign odontogenic tumours corresponded to 538 cases (98.9%) and malignant tumours were only six cases (1.1%).
CONCLUSIONS
In our population, odontoma was the most frequent odontogenic tumour followed by ameloblastoma and cemento-ossifying fibroma. Malignant odontogenic tumours were very rare. The results of this study are similar to reports from America, but there are some differences concerning the data from Africa and Asia.
Topics: Humans; Ameloblastoma; Odontoma; Retrospective Studies; Cementoma; Chile; Odontogenic Tumors; World Health Organization
PubMed: 37823289
DOI: 10.4317/medoral.26008